Mercer Global Advisors
ADCT icon

Mercer Global Advisors’s ADC Therapeutics ADCT Stock Holding History

Mercer Global Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72K Buy
+3,476
New +$10.1K ﹤0.01% 5437

Other funds holding ADCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Mercer Global Advisors's ADCT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 3,476 shares worth $3.72K. The stake represents ﹤0.01% of the portfolio and ranks #5437 among its holdings.

74 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Mercer Global Advisors held 3,476 shares of ADC Therapeutics worth $3.72K as of Q2 2026.
  • ADC Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5437 holding.
  • 74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.